The earnings call reflects a positive sentiment overall, as Nautilus Biotechnology achieved significant scientific milestones, established strategic collaborations, and demonstrated strong financial management. However, there are challenges in terms of market development for proteoforms and limited immediate revenue generation from current collaborations.

Company Guidance

In the second quarter of 2025, Nautilus Biotechnology achieved significant milestones, notably through the release of a manuscript demonstrating their platform's ability to resolve proteoforms with high resolution and reproducibility. The platform showed a median coefficient of variation (CV) of 1.5% within experiments and around 5% across different setups, compared to up to 80% in existing methods. The assay displayed sensitivity to changes in proteoform abundance by a factor of over 1,000, and accurately quantified low-abundance forms, such as tau present at 0.1% of total tau. Nautilus also noted a decrease in operating expenses to $17.1 million, an 18% reduction from the previous year, with a net loss of $15 million. The company maintains a strong cash position of approximately $179.5 million, projecting a cash runway through 2027. Nautilus continues to focus on refining their broadscale assay and expanding collaborations, having signed two agreements with major U.S. research institutes.

Significant Scientific Milestone Achieved

Nautilus publicly shared its first preprint featuring novel data using the Nautilus platform, showcasing unprecedented dynamic range and industry-leading reproducibility in proteoform data.

Proteoform Analysis Breakthrough

The Nautilus platform demonstrated the ability to measure proteoforms at a single molecule level, offering insights into tau biology and potential advancements in neurodegenerative disease diagnostics and therapeutics.

Successful Collaborations Established

Nautilus signed two collaborations with major U.S. research institutes to demonstrate platform capabilities and enable new biological insights in Alzheimer's disease.

Strong Financial Management

Operating expenses for Q2 2025 were $17.1 million, an 18% decrease from the same period in 2024, with a net loss of $15.0 million compared to $18.0 million in the prior year.

Solid Cash Position

The company ended the quarter with approximately $179.5 million in cash, cash equivalents, and investments, projecting a cash runway through 2027.

Nautilus Biotechnolgy (NAUT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NAUT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	-0.15 / -	-0.13	―	―	―
Jul 31, 2025	2025 (Q2)	-0.15 / -0.12	-0.14	14.29% (+0.02)	―
Apr 29, 2025	2025 (Q1)	-0.15 / -0.13	-0.15	13.33% (+0.02)	―
Feb 27, 2025	2024 (Q4)	-0.15 / -0.14	-0.14	0.00% (0.00)
Oct 29, 2024	2024 (Q3)	-0.17 / -0.13	-0.13	0.00% (0.00)
Jul 30, 2024	2024 (Q2)	-0.16 / -0.14	-0.13	-7.69% (-0.01)	―
Apr 30, 2024	2024 (Q1)	-0.16 / -0.15	-0.12	-25.00% (-0.03)	―
Feb 28, 2024	2023 (Q4)	-0.16 / -0.14	-0.11	-27.27% (-0.03)
Oct 31, 2023	2023 (Q3)	-0.15 / -0.13	-0.11	-18.18% (-0.02)	―
Aug 02, 2023	2023 (Q2)	-0.15 / -0.13	-0.12	-8.33% (-0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NAUT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$0.76	$0.76	0.00%
Apr 29, 2025	$0.68	$0.73	+7.35%
Feb 27, 2025	$1.43	$1.17	-18.18%
Oct 29, 2024	$2.81	$2.77	-1.42%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Nautilus Biotechnolgy (NAUT) report earnings?

Nautilus Biotechnolgy (NAUT) is schdueled to report earning on Nov 04, 2025, Before Open (Confirmed).

What is Nautilus Biotechnolgy (NAUT) earnings time?

Nautilus Biotechnolgy (NAUT) earnings time is at Nov 04, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NAUT EPS forecast?

NAUT EPS forecast for the fiscal quarter 2025 (Q3) is -0.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing